Phase II study of marimastat (BB-2516) in malignant melanoma: A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group

Investigational New Drugs

Volumn 20, Issue 4, 2002, Pages 431-437

  Quirt, Ian ^a   Bodurtha, Audley ^b,c   Lohmann, Reinhard ^d   Rusthoven, James ^e   Belanger, Karl ^f   Young, Vincent ^b   Wainman, Nancy ^g   Steward, William ^g,h   Eisenhauer, Elizabeth ^g  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c Nova Scotia Cancer Centre   (Canada)

^d London Regional Cancer Centre   (Canada)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f NOTRE DAME HOSPITAL   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Marimastat; Melanoma; Phase II; Translational study

Indexed keywords

MARIMASTAT; MATRIX METALLOPROTEINASE;

ADULT; AGED; ANOREXIA; APOPTOSIS; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENZYME ACTIVITY; FATIGUE; FEMALE; FIBROSIS; HUMAN; INFLAMMATION; MALE; MELANOMA; METASTASIS; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR NECROSIS; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC PROTOCOLS; BIOPSY; CANADA; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MELANOMA; METALLOENDOPEPTIDASES; MIDDLE AGED;

EID: 0036830078     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020625423524     Document Type: Article

References (9)

1. Comis RL: DTIC (NSC-45388) in malignant melanoma: A perspective. Cancer Treat Rep 60:165-176, 1976
2. Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HKB, Verma S, Armitage GR, Zee B, Bennett K: Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 14:2083-2090, 1996
3. Kirkwood JM, Ernstoff M: Melanoma: Therapeutic options with recombinant interferons. Semin Oncol 13 Suppl 5:7-12, 1985
4. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, Doroshow JH, Aronson FR, Rubenstein LV, Mier JW: A randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon-α 2A in patients with advanced melanoma. J Clin Oncol 11:1969-1977, 1993
5. Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: A review of antitumor activity. Ann Oncol 6:967-974, 1995
6. Brown PD, Bloxidge RE, Stuart NSA, Gatter KC, Carmichael J: Association between expression of activated 72-kilodalton gelatinase and tumour spread in non-small cell lung cancer. J Natl Cancer Inst 85:574-578, 1993
7. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Activity of type IV collagenases in benign and malignant breast tissue. Br J Cancer 67:1126-1131, 1993
8. Smyth-Templeton N, Brown PD, Levy AT, Margulies IM, Liotta LA, Stetler-Stevenson WG: Cloning and characterization of human melanoma interstitial collagenase. Cancer Res 50:6184-6191, 1990
9. Chirivi RGS, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, Giavazzi R: Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58:460-464, 1994